

RESEARCH

Open Access

Multiple microRNAs targeted to internal ribosome entry site against foot-and-mouth disease virus infection *in vitro* and *in vivo*

Yanyan Chang^{1,2}, Yongxi Dou¹, Huifang Bao¹, Xuenong Luo¹, Xuerong Liu^{1,2}, Kebin Mu^{1,2}, Zaixin Liu¹, Xiangtao Liu¹ and Xuepeng Cai^{1,3*}

Abstract

Background: Foot-and-mouth disease virus (FMDV) causes a severe vesicular disease in domestic and wild cloven-hoofed animals. Because of the limited early protection induced by current vaccines, emergency antiviral strategies to control the rapid spread of FMD outbreaks are needed.

Here we constructed multiple microRNAs (miRNAs) targeting the internal ribosome entry site (IRES) element of FMDV and investigated the effect of IRES-specific miRNAs on FMDV replication in baby hamster kidney (BHK-21) cells and suckling mice.

Results: Four IRES-specific miRNAs significantly reduced enhanced green fluorescent protein (EGFP) expression from IRES-EGFP reporter plasmids, which were used with each miRNA expression plasmid in co-transfection of BHK-21 cells. Furthermore, treatment of BHK-21 cells with Bi-miRNA (a mixture of two miRNA expression plasmids) and Dual-miRNA (a co-cistronic expression plasmid containing two miRNA hairpin structures) induced more efficient and greater inhibition of EGFP expression than did plasmids carrying single miRNA sequences.

Stably transformed BHK-21 cells and goat fibroblasts with an integrating IRES-specific Dual-miRNA were generated, and real-time quantitative RT-PCR showed that the Dual-miRNA was able to effectively inhibit the replication of FMDV (except for the Mya98 strain) in the stably transformed BHK-21 cells.

The Dual-miRNA plasmid significantly delayed the deaths of suckling mice challenged with 50x and 100x the 50% lethal dose (LD₅₀) of FMDV vaccine strains of three serotypes (O, A and Asia 1), and induced partial/complete protection against the prevalent PanAsia-1 and Mya98 strains of FMDV serotype O.

Conclusion: These data demonstrate that IRES-specific miRNAs can significantly inhibit FMDV infection *in vitro* and *in vivo*.

Keywords: Foot-and-mouth disease virus, MicroRNA, Internal ribosome entry site, Transformed cell clones, Antiviral effect, Flow cytometry, Real-time quantitative RT-PCR

Background

Foot-and-mouth disease is an acute, highly contagious and economically important disease that affects domestic and wild cloven-hoofed animals, such as cattle, swine, sheep and goats [1,2]. The etiological agent, foot-and-mouth disease virus (FMDV), belongs to the genus

Aphthovirus in the family *Picornaviridae* [3]. There are seven serotypes of FMDV and multiple subtypes [4-6]. The viral genome is composed of a positive-sense, single-stranded RNA that functions as an mRNA and contains a unique open reading frame (ORF) encoding a viral polyprotein. This polyprotein is co-translationally processed, largely by virus-encoded proteases, to produce about 15 mature proteins plus many different precursors [7-9]. Initiation of FMDV RNA translation is directed by a large RNA *cis*-acting element of about 440 nucleotides (nts) termed the internal ribosome entry site (IRES) element

* Correspondence: caixp@vip.163.com

¹State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, P. R. of China

³China Animal Disease Prevention Control Center, Beijing 100125, P. R. of China
Full list of author information is available at the end of the article

[10,11]. This region is predicted to adopt a secondary structure that mediates RNA–protein interactions essential for ribosome recognition [12,13]. The RNA genome also has to act as the template for RNA replication [14]. During this process, the genome undergoes rapid mutation at average rates of 10^{-3} to 10^{-5} substitution per nucleotide copied, due to the lack of proofreading mechanism of the RNA-dependent RNA polymerase (RdRp) [15–17]. Thus, FMDV populations form as “clouds” of mutants, or mutant distributions, termed viral quasispecies [18–21]. FMDV evolution is strongly influenced by high mutation rates and the dynamics of viral quasispecies, and results in ever-changing targets for antiviral strategies, including vaccination [22,23].

Although the current FMD vaccines play an essential role in the control of FMD outbreaks, they fail to induce an immediate protective response. There is a “window”, a so-called immune blank period, of susceptibility to FMDV infection in vaccinated animals at 1–7 days post-immunization [24,25]. Hence, alternative emergency strategies are needed for rapid control of FMDV outbreaks. Small interference RNAs (siRNAs) have been widely studied as a means of inhibiting FMDV replication *in vitro* and *in vivo* [26–33]. However, the efficacy and specificity of this inhibition could be completely abolished by a single point mutation in the target sequence [34–37], potentially limiting the usefulness of this approach against rapidly mutating and mutated viruses such as FMDV [38].

Therefore, the use of microRNA (miRNA), rather than siRNA, may be necessary, to cause mRNA degradation in a sequence-specific manner or gene silencing in an imperfectly base-paired manner [39,40]. Here we report that multiple vector-delivered, IRES-specific miRNAs effectively and specifically silence EGFP (enhanced green fluorescent protein) expression from IRES-EGFP fusion protein reporter plasmids in BHK-21 cells and inhibit virus replication in FMDV-IRES-specific Dual-miRNA-transformed BHK-21 cells and suckling mice. Additionally, a high-efficiency Dual-miRNA targeted to the IRES element was integrated stably into the chromosomal DNA of goat fibroblasts, for the future creation of transgenic animals resistant to FMDV infection.

Results

IRES-specific miRNAs on plasmids silence reporter gene expression in BHK-21 cells

Specific silencing of EGFP expression by a single miRNA

To determine if miRNAs specifically targeting the IRES element could effectively silence EGFP expression from IRES-EGFP reporter plasmids, we constructed four IRES-specific miRNA expression plasmids (pmiR153, pmiR220, pmiR242 and pmiR276; Figure 1A) and three IRES-EGFP reporter plasmids (pHN/IRES-EGFP, pFC/IRES-EGFP and pJS/IRES-EGFP; Figure 1B). Each miRNA expression

plasmid (including pmiR-NC, the negative control; Table 1) was, with each reporter plasmid (including p3D-GFP, a control for nonspecific effects [41]), used to co-transfected BHK-21 cells at a molar ratio of 1:1 (w/w). The cells were observed continuously under the fluorescence microscope and analyzed by flow cytometry 48 h post-transfection. Four IRES-specific miRNAs significantly reduced EGFP expression from the IRES-EGFP reporter plasmids but not from the p3D-GFP plasmid (Figure 2). The pmiR-NC plasmid showed no visible changes in EGFP expression (Figure 2). pmiR242 (except with pHN/IRES-EGFP) and pmiR276 yielded more significant reductions of IRES-EGFP expression, compared with pmiR153 and pmiR220 (Table 2).

Enhanced silencing of EGFP expression by Bi-miRNA and Dual-miRNA

pmiR242 and pmiR276 were used for further analysis of effective inhibition of IRES-EGFP reporter expression in BHK-21 cells. Co-transfection of a mixture of these two IRES-specific miRNA expression plasmids (pmiR242 and pmiR276, Bi-miRNA) with any of the three IRES-EGFP reporter plasmids resulted in a 78.4%–88.3% reduction in intensity of EGFP fluorescence, as compared with the individual plasmids of pmiR242 (44.3%–71.4%) and pmiR276 (60.5%–81.4%) (Figure 2, Table 2).

To further improve the specific silencing, we constructed pmiR242 + 276 (Dual-miRNA), a co-cistronic expression plasmid containing two IRES-specific miRNA hairpin structures (Figure 1A). BHK-21 cells were co-transfected with the Dual-miRNA plasmid pmiR242 + 276 and each IRES-EGFP reporter plasmid. Remarkably, the results showed that pmiR242 + 276 was more effective than pmiR153, pmiR220, pmiR242, pmiR276, or Bi-miRNA, and displayed 83.6%–96.6% inhibition of EGFP expression at 48 post-transfection (Figure 2, Table 2).

Stable expression of IRES-specific Dual-miRNA confers effective inhibition of FMDV replication

Selection of stably FMDV-IRES-specific Dual-miRNA-transformed BHK-21 cells and goat fibroblasts

BHK-21 cells transfected with pEGFP-miR242 + 276 (Figure 1A) and goat fibroblasts transfected with pmiR242 + 276 were grown under Blasticidin (3 μ g/mL) selection for 7 days. The populations of Blasticidin-resistant (Blasticidin^R) clones were continuously obtained in selective culture at serial passages. To determine the presence of Dual-miRNA in the transformed BHK-21 cells (the 6th passage) and goat fibroblasts (the 3rd passage), the clones were analyzed by PCR using a specific forward primer (5'-AGCAGGCTTTAAAGGGAGGTAGTG-3') and reverse primer (5'-CTCTAGATCAAC CACTTTTGT-3'). As expected, a 410-bp (base pairs) fragment was amplified by using PCR from DNA extraction of cellular




Figure 1 Schematic representations of (A) FMDV-specific miRNAs and (B) IRES-EGFP expression plasmids. 5' and 3' miR flanking regions are represented as grey. Procedures for the construction of single miRNA (pmiR153, pmiR220, pmiR242, and pmiR276), Dual-miRNAs (pmiR242 + 276 and pEGFP-miR242 + 276) and the reporter plasmids (pHN/IRES-EGFP, pFC/IRES-EGFP, and pJS/IRES-EGFP) are described in Methods.

suspension from DNA extracted from every Blasticidin^R clone (Figure 3A). DNA sequencing revealed that the DNA containing the precursor miRNAs (pre-miRNAs) was stably integrated into the chromosomes of all the Blasticidin^R BHK-21 cells and goat fibroblasts. Green fluorescence was observed in the cytoplasm of the transformed BHK-21 cells (Figure 3B), suggesting that the Dual-miRNA (pEGFP-miR242 + 276) could be expressed and processed into individual IRES-specific miRNAs.

Analysis of inhibition of FMDV replication in Dual-miRNA-transformed BHK-21 cells

To examine the effect of IRES-specific miRNAs on FMDV replication, supernatants from virus-infected pEGFP-miR242 + 276-transformed BHK-21 cells were harvested at designated time points, total RNA was extracted, and FMDV copy numbers were measured by subjecting the total RNA samples to real-time quantitative RT-PCR. The results were very reproducible, based

Table 1 Oligonucleotides of vector-delivered pre-miRNAs

Name	Single stranded DNA sequences (5' → 3')	Position	
pmiR153	Top strand	TGCTGCTCCTTGGAACAAGGACCCAGTTTTGGCCACTGACTGACTGGGTCCTTTACCAAGGAG	151-171
	Bottom strand	CCTGCTCCTTGGAATAAGGACCCAGTCAGTCAGTGGCCAAAAC TGGGTCCTTGTACCAAGGAGC	
pmiR220	Top strand	TGCTGGCACGGCAACTTTACTGTGAAGTTTTGGCCACTGACTGACTTCACAGTAGITGCCGTGC	220-240
	Bottom strand	CCTGGCACGGCAACTACTGTGAAGTCAGTCAGTGGCCAAAAC TTACAGTAAAGTTGCCGTGCC	
pmiR242	Top strand	TGCTGCCACCTTAAGGTGACACTGATGTTTTGGCCACTGACTGACATCAGTGCCTTAAGGTGG	243-263
	Bottom strand	CCTGCCACCTTAAGGACACTGATGTCAGTCAGTGGCCAAAAC ATCAGTGTACCTTAAGGTGGC	
pmiR276	Top strand	TGCTGCACTGGTGACAGGCTAAGGATGTTTTGGCCACTGACTGACATCCTTAGTGTACCAGTG	277-297
	Bottom strand	CCTGCACTGGTGACACTAAGGATGTCAGTCAGTGGCCAAAAC ATCCTTAGCCTGTACCAGTGC	
pmiR-NC	Top strand	TGCTGAAATGTAAGTACTGCGGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATT	Heterologous
	Bottom strand	CCTGAAATGTAAGTACTGCGGTGGAGACGTCAGTCAGTGGCCAAAAC GTCTCCACGGCAGTACATTC	

The sense sequences of predicted miRNAs targeting the FMDV IRES are shown in **bold** and *italic*.




Table 2 Efficiencies of miRNAs targeting the FMDV IRES in inhibiting EGFP expression in BHK-21 cells as assayed by flow cytometry

Reporter plasmid	Inhibition efficiency of each miRNA (%)					
	pmiR153	pmiR220	pmiR242	pmiR276	Bi-miRNA	Dual-miRNA
pHN/IRES-EGFP	72.2%	56.7%	44.3%	81.4%	84.7%	95.0%
pFC/IRES-EGFP	38.7%	47.9%	71.4%	60.5%	88.3%	96.6%
pJS/IRES-EGFP	64.6%	37.5%	68.8%	62.5%	78.4%	83.6%

Bi-miRNA, a mixture of pmiR242 and pmiR276 plasmids; Dual-miRNA, a co-cistronic expression plasmid (pmiR242 + 276) containing two pre-miRNA (pmiR242 and pmiR276) hairpin structures. Percentage inhibition in each co-transfected (vector-delivered miRNAs and the reporter plasmids) cell population was calculated by comparison with the control cells transfected only with the same reporter plasmid at 48 h post-transfection.




Figure 3 PCR analysis and morphological observation of the FMDV IRES-specific Dual-miRNA-transformed cell clones. Cultured cells were transfected with pEGFP-miR242 + 276 (BHK-21 cells) or pmiR242 + 276 (goat fibroblasts), and the resultant stably transformed clones were obtained by Blasticidin^R selection as described in Methods. **(A)** The PCR products from harvested cells were electrophoresed through 0.8% agarose gels and identified under UV light. As a negative control, a mixture of the total DNA extracted from normal BHK-21 cells and goat fibroblasts was amplified using the same specific primer pairs. **(B)** The green fluorescence in the pEGFP-miR242 + 276-transformed BHK-21 cells (left) and the pmiR242 + 276-transformed goat fibroblasts (right) were visualized with a fluorescence microscope and a light microscope, respectively.

on the cycle threshold (Ct) values in duplicate measurements. Normal BHK-21 cells were infected with the same FMDVs as parallel controls. In cells infected with three vaccine strains of FMDV serotype O (O/HN/CHA/93), A (AF72), and Asia 1 (Asia 1/Jiangsu/China/2005) and the prevalent PanAsia-1 strain of FMDV serotype O (O/Tibet/China/1/99), the difference in mean Ct values between test samples and control samples showed that pEGFP-miR242 + 276 had the effect of inhibition on the replication of the indicated FMDV in the Dual-miRNA-transformed BHK-21 cells at 36 h post-infection (h.p.i) (Table 3). However, viral RNA replication of the prevalent Mya98 strain of FMDV serotype O (O/CHN/Mya98/33-P) was not inhibited in the Dual-miRNA-transformed BHK-21 cells (Table 3). The results show that IRES-specific miRNAs can significantly inhibit viral infection of the selected FMDVs (except for O/CHN/Mya98/33-P) *in vitro*.

Antiviral activity of vector-delivered Dual-miRNA in suckling mice

The IRES-specific miRNAs were tested against challenge by the same viruses (O/HN/CHA/93, AF72, Asia 1/Jiangsu/China/2005, O/Tibet/China/1/99, and O/CHN/

Mya98/33-P) *in vivo*. All negative control mice treated with 1 × PBS survived (Figure 4). All the positive control mice, which were treated with 50 LD₅₀ and 100 LD₅₀ of the respective FMDVs, died within 42 h (Figure 4). In the O/HN/CHA/93, AF72, and Asia 1/Jiangsu/China/2005 challenge groups, mice that received injection of mixtures of the corresponding viruses and pmiR242 + 276 were not protected from either 50 LD₅₀ or 100 LD₅₀ of FMDV. However, the times at which 50% and 100% of the mice had died were delayed for more than 6 h for each of the FMDV-pmiR242 + 276-injected groups (Figure 4A, B and C). In the groups challenged with of 50 LD₅₀ and 100 LD₅₀ O/Tibet/China/1/99 of FMDV, 3 of the 4 mice in each group treated with mixtures of the indicated virus and pmiR242 + 276 survived for 7 days of observation (Figure 4D). Among the mice challenged with 50 LD₅₀ and 100 LD₅₀ O/CHN/Mya98/33-P, 4 of 4 and 3 of 4 mice, respectively, injected with mixtures of the indicated FMDV and pmiR242 + 276 also survived over the same period of time (Figure 4E).


Discussion

miRNAs play an important role in post-transcriptional gene silencing (PTGS), inhibiting translation at and/or following initiation, as RNA interference (RNAi) [42-44].

Table 3 Real-time quantitative RT-PCR analysis of the inhibition of FMDV replication in pEGFP-miR242 + 276-transformed BHK-21 cells, compared with normal BHK-21 cells

FMDV	Ct values (mean)					
	12 h.p.i.	24 h.p.i.	36 h.p.i.	48 h.p.i.	60 h.p.i.	72 h.p.i.
O/Tibet/China/1/99	34.61 ± 0.32/37.73 ± 0.07	36.20 ± 0.09/38.76 ± 0.25	35.98 ± 0.83/36.09 ± 0.12	37.55 ± 0.22/36.75 ± 0.44	37.62 ± 0.51/26.92 ± 0.21	36.08 ± 0.08/28.49 ± 0.39
O/HN/CHA/93	36.45 ± 0.05/35.65 ± 0.66	36.85 ± 0.57/31.32 ± 0.10	33.41 ± 0.15/28.62 ± 0.40	28.54 ± 0.10/28.82 ± 0.49	26.84 ± 0.16/26.34 ± 0.11	26.34 ± 0.30/26.54 ± 0.22
O/CHN/Mya98/33-P	16.70 ± 0.10/16.27 ± 0.23	15.17 ± 0.02/14.57 ± 0.04	11.81 ± 0.30/12.44 ± 0.14	8.43 ± 0.59/14.16 ± 0.41	7.49 ± 0.31/9.16 ± 0.04	13.68 ± 0.10/15.02 ± 0.59
AF72	30.97 ± 0.08/25.23 ± 0.17	36.23 ± 0.78/30.44 ± 0.41	36.36 ± 0.18/35.02 ± 0.79	38.45 ± 1.07/25.21 ± 0.92	36.32 ± 0.94/10.32 ± 0.71	37.13 ± 0.15/11.16 ± 0.31
Asia1/Jiangsu/China/2005	36.73 ± 0.18/34.16 ± 0.68	37.12 ± 0.11/35.65 ± 0.19	37.28 ± 0.39/35.46 ± 0.04	35.42 ± 0.09/27.39 ± 0.20	36.62 ± 0.57/17.84 ± 0.63	38.59 ± 0.77/16.68 ± 0.44


Viral supernatants were collected at 12, 24, 36, 48, 60, and 72 h.p.i., and the Ct values were derived from two parallel experiments (treatment/control).



It is believed that miRNAs are essential regulators of cell fate determination, such as in early development, and of cellular proliferation and differentiation, apoptosis, and pathogen-host interactions [45,46]. There are few reports of the use of miRNAs as anti-FMDV agents, although miRNA has more potential than siRNA to silence FMDV replication [41]. In this study, the FMDV IRES was selected as the target of vector-delivered miRNAs and the inhibitory effects of these FMDV-specific miRNAs on IRES-EGFP expression, replication of the genomic RNA, and the pathogenicity of FMDV were examined in BHK-21 cells and/or suckling mice.

The FMDV IRES consists of a highly structured region having five structural domains [47]. The different domains have different functions in interacting with eukaryotic translation initiation factors (eIFs) to contribute to translational initiation [12,48-50]. Antisense transcripts from the 5' region, including the proximal part of the IRES element and the functional initiator AUG codons, inhibited FMDV (serotype C) infection [51]. This inhibition, which reached values up to 90%, was dose-dependent and FMDV-specific, and also affected heterologous FMDV RNAs of serotypes O and A [52]. Rosas et al. have reported that the 156-nt transcript complementary to the FMDV translation initiation region in the viral RNA has effective antiviral activity when stably expressed in FMDV-susceptible cells [53]. In addition, small synthetic non-infectious RNA molecules

corresponding to the IRES element can induce rapid, effective, and wide-range protection against FMDV infection [54]. It has been argued that the IRES element might not be accessible to RNAi [55,56]. In our experiments, the four FMDV-miRNAs targeted the GNRA motif (pmiR153), the proximal part of the ACCC loop (pmiR220) and the stem (pmiR242) of the central region (domain 3), and the root-linker-stem (pmiR276) within domain 3-4 of the IRES element, respectively (Figure 5A). Domain 3 of the FMDV IRES is unique in its ability to interact with each of the other domains, including the entire IRES [49]. The GNRA motif of the apical loops of domain 3 appears to be responsible for the organization of the adjacent stem-loops [47]. Another conserved sequence, the ACCC loop, is a candidate to interact with poly(rC) binding proteins (PCBP) [57]. Certain nts of domain 4 are involved in the interactions with proteins that play an essential role during internal initiation [58]. Here, the FMDV-specific miRNAs targeting the root-linker-stem within domain 3-4 and the stem of domain 3 provided the most efficient silencing, followed by those targeting the GNRA motif and the proximal part of the ACCC loop in domain 3 of the IRES element. The diversity of base-pair conformations in the arm of GNRA motif and the stem of domain 3 (Figure 5B) might have influenced the inhibitory effect of pmiR153 (with pHN/IRES-EGFP and pJS/IRES-EGFP) and pmiR242 (with pHN/IRES-EGFP) on EGFP expression from the reporter



plasmids (Table 2). These results suggest that conformational changes are likely to be important effectors of miRNA function and the conserved regions involving Watson-Crick base pairing within the exposed part of FMDV IRES could be potential target sequences for miRNA-induced gene silencing. We also observed that the silencing effect in BHK-21 cells could be enhanced by use of Bi-miRNA (pmiR242 and pmiR276) co-transfected with the IRES-EGFP expression reporter plasmids (Table 2). Moreover, the silencing effect of vector-

delivered Dual-miRNA (pmiR242 + 276) was much stronger than either a single miRNA or Bi-miRNA (Table 2). These strategies have been used for to improve the antiviral effect, and to defend against the high genetic variability of the virus and the production of viral escape mutants [59].

To analyze the antiviral effect, all serotypes of FMDV (including vaccine strains and the prevalent strains) isolated from China, except for the SEA topotype of FMDV serotype A [60], were used to inoculate the IRES-specific Dual-miRNA-transformed BHK-21 cells and for virus

challenge in suckling mice. In the suckling mice, the Dual-miRNA plasmid was delivered with the virus challenge, differing from previous studies [30,33,38,61]. Unexpectedly, the IRES-specific Dual-miRNA had no inhibitory effect on the RNA replication of FMDV O/CHN/Mya98/33-P *in vitro* despite its efficacy *in vivo* (Table 3, Figure 4E). The potential for the rapid, selective replication of the virus *in vitro* would increase the possibility of genetic changes and diversity in the populations of progeny virus (Table 3) [62,63]. Consequently, the antiviral effect was inversely proportional to the number of mismatches between the miRNA and the targeted IRES sequence, although the predicted secondary structure was tolerated (Figure 5A) [64,65]. In addition, the different gene silencing efficiencies and expression levels of the mature IRES-specific miRNAs could not guarantee complete inhibition of FMDV replication in the Dual-miRNA-transformed BHK-21 cells, and suggested that the tandem arrangement of pre-miRNAs and the reporter gene might influence the antiviral efficacy of FMDV-specific miRNA-expressing plasmids (Figure 1A) [66].

Conclusion

Our data demonstrate that FMDV replication can be significantly inhibited by FMDV-specific miRNAs targeted to the IRES element *in vitro* and *in vivo*. Blasticidin^R clones of goat fibroblasts with chromosomally integrated FMDV-IRES-specific Dual-miRNA genes have also been obtained, in order to produce transgenic animals resistant to FMDV. We propose that multiple miRNAs could be effective new tools for the control of rapidly spreading FMD outbreaks in the future.

Methods

Cells, animals, and viruses

BHK-21 cells were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Hyclone). Goat fibroblasts were kindly provided by Prof. Baohua Ma (Northwest Agriculture & Forestry University) and cultured in DMEM/F12 nutrient mixture (Gibco) (containing 1.5 g/L sodium bicarbonate) supplemented with 10% FBS. All cell lines were incubated at 37°C with 5% CO₂. Kunming White suckling mice, 2–3 days old and weighing 3–4 g, were purchased from Lanzhou Institute of Biological Products. Five FMDV isolates, O/Tibet/China/1/99 [PanAsia-1 strain of ME-SA (Middle East-South Asia) topotype, AF506822], O/HN/CHA/93 (vaccine strain of Cathay topotype) [67], O/CHN/Mya98/33-P [Mya98 strain of SEA (South-East Asia) topotype, JQ973889], and AF72 (vaccine strain of Asia topotype) [68], Asia 1/Jiangsu/China/2005 (vaccine strain of SEA topotype, EF149009), were preserved and provided by OIE/National Foot-and-Mouth Disease Reference Laboratory of China.

Design and generation of vector-delivered miRNA plasmids

Four potential miRNAs were developed from the complete IRES nucleotide sequence of FMDV O/HN/CHA/93 strain by using the miRNA design tool on Invitrogen's web site tool (<http://rnaidesigner.invitrogen.com/rnaexpress/>, Table 1). Oligonucleotides of the pre-miRNAs forward and reverse strands were synthesized, annealed, and cloned into pcDNA[™]6.2-GW/miR vector (Invitrogen) under the control of P_{CMV} and a transcriptional termination signal (TK pA), following the manufacturer's protocol. These plasmids were designated pmiR153, pmiR220, pmiR242, and pmiR276 (Figure 1A). For subcloning, *Bam*H I/*Xho* I digested products from pmiR276 were inserted into pmiR242 at its *Bgl* II/*Xho* I sites, resulting in pmiR242 + 276, a Dual-miRNA plasmid containing two IRES-specific miRNA hairpin structures (Figure 1A). Then, *Bam*H I/*Xho* I fragments were digested from pmiR242 + 276 and cloned into pcDNA[™]6.2-GW/EmGFP-miR using a BLOCK-iT[™] Pol II miR RNAi Expression Vector Kit with EmGFP (Invitrogen), to generate the recombinant plasmid pEGFP-miR242 + 276 expressing EGFP (Figure 1A). The pcDNA6.2-GW/miR-negative control plasmid (pmiR-NC) was provided by Invitrogen (Table 1) and has no sequence homology with FMDV. All of these plasmids were confirmed by DNA sequencing.

Construction of reporter plasmids

To provide a reporting system for monitoring miRNA function, three recombinant reporter plasmids pHN/IRES-EGFP, pFC/IRES-EGFP, and pJS/IRES-EGFP were constructed as follows. Briefly, IRES fragments of each FMDV of vaccine strains of serotypes A, O, and Asia 1 were obtained using RT-PCR amplification with a sense *Bam*H I-adapter primer and an antisense primer, from genomic RNAs extracted from BHK-21 cell-adapted FMDV strains (O/HN/CHA/93, AF72, and Asia 1/Jiangsu/China/2005). The EGFP sequence was amplified from the pEGFP-N1 vector (Clontech) using specific primers, and the amplification products of the FMDV-IRES fusion with EGFP were constructed by use of overlapping PCR (PrimeSTAR; TaKaRa). The PCR products were then cloned into *Bam*H I/*Xho* I-digested pcDNA[™]6.2-GW/miR vector (Figure 1B). The sequences of the inserts were confirmed by restriction enzyme analysis and DNA sequencing. The reporter plasmid p3D-GFP used as a control for nonspecific effects was kindly provided by Dr. Junzhen Du [41].

Cell transfection and miRNA silencing of EGFP expression

BHK-21 cells were seeded in 6-well plates (Nunc) within 24 h before transfection. Monolayers (about 90–95% confluent) of BHK-21 cells were transiently co-transfected with 5, 10, or 20 µg of each reporter plasmid and 5, 10, or 20 µg of each miRNA expression plasmid (including a

mixture of pmiR242 and pmiR276, Bi-miRNA) or pmiR-NC construct at an optimal ratio with 10 μ L Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. The cells were examined by fluorescence microscopy (Leica) for EGFP expression at 12, 24, 36, and 48 h post-transfection.

Specific silencing of target genes to restrain EGFP expression was also examined by flow cytometry at 48 h post-transfection as follows. The co-transfected cell monolayers were dissociated with 200 μ L of 0.25% trypsin after washing with 1 \times PBS two times, and resuspended in a total volume of 1 mL 1 \times PBS/well. After three washes with 1 \times PBS, they were diluted to 1 \times 10⁵–1 \times 10⁷ cells/mL in 1 \times PBS for analysis by FACS-Calibur (Becton-Dickinson), according the manufacturer's protocol. The EGFP fluorescence was detected by optimal excitation at 488 nm and emission at 508 nm, and the fluorescence intensity values were calculated as the percentage of the cell populations.

Analysis of FMDV replication in Dual-miRNA-transformed BHK-21 cells

To establish BHK-21 cells stably transformed with Dual-miRNA, 10 μ g pEGFP-miR242 + 276 plasmid was used to transfect 95% confluent BHK-21 cells in 35-mm plates using Lipofectamine 2000 as described above. At 4–6 h post-transfection, the OptiMEM-1 (Gibco) suspended transfection complex was removed and the cells were trypsinized, diluted 10-fold, and seeded on microtitre plates (Greiner Bio-one). The cells were maintained under DMEM containing 10% FBS and 3 μ g/mL Blastidicin (Invitrogen), by means of selection of resistant forms. The selection medium was changed every 2–3 days until the resultant BHK-21 cell cultures reached 100% confluency.

The stable cell monolayers were grown at a cell density of 1–2 \times 10⁵/well in 6-well plates, and washed twice with 1 \times PBS. Viral suspensions titrated at 30–100 plaque forming units (PFU) per 1 mL were used for virus challenge. A multiplicity of infection (MOI) of 5–50 PFU of each virus per 200 μ L in DMEM was added to each well. After 1 h of adsorption, the inoculum was removed and the cells were washed twice with DMEM. Then, 2 mL of DMEM supplemented with 2% FBS and 1% antibiotic (50 μ g/mL Spectinomycin, Sigma) was added to each well and the plates was incubated at 37°C with 5% CO₂. Subsequently, supernatants were collected at designated time points, and frozen at –80°C for later real-time quantitative RT-PCR analysis as described previously [41].

Virus challenge assay in suckling mice

To investigate the anti-FMDV activity of vector-delivered IRES-specific Dual-miRNA plasmid *in vivo*, suckling mice were used for virus challenge assay as

previously described [31]. Four suckling mice in each group were treated by subcutaneous injection in the neck of mixtures of a total volume of 200 μ L comprising 50 or 100 LD₅₀ of each virus in 50 μ L 1 \times PBS mixed with 200 μ g of pmiR242 + 276 plasmid in 150 μ L 1 \times PBS. Control mice were inoculated subcutaneously in the neck with the same titer of FMDV (positive control), or 1 \times PBS (negative control). All mice were monitored every 6 hours up to 7 days.

Establishment of FMDV-specific Dual-miRNA-transformed clones of goat fibroblasts

Goat fibroblasts were plated in 60-mm diameter dishes with 5 \times 10⁵ cells in 10% FBS-containing DMEM/F12 24 h before transfection. The cells were transfected with 10 μ g pmiR242 + 276 plasmid. After 4–6 h, the transfection complex was removed, and 10% FBS in DMEM/F12 with Blastidicin (3 μ g/mL) was added to the cells. Cells resistant to Blastidicin were selected for one week, with medium changes about every 2–3 days. Independent Blastidicin^R clones were picked and expanded in the presence of Blastidicin (2 μ g/mL) to avoid loss of the integrated DNAs. Cell stocks of IRES-specific Dual-miRNA-transformed clones were identified by PCR assay, and kept frozen in liquid nitrogen for further study.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

YYC planned the study, constructed plasmids, and drafted the manuscript. YXD was involved in selection of the transformed cell clones. HFB performed gene-silencing experiments in BHK-21 cells. XNL, XRL, and KBM participated in the experiments on antiviral effects *in vitro* and *in vivo*. ZXL and XTL collected the field isolates and delivered background information, and XPC conceived the study. All authors reviewed and approved the final manuscript.

Acknowledgments

We thank Prof. Baohua Ma (Northwest Agriculture & Forestry University) and our colleague Dr. Junzhen Du for providing goat fibroblasts and the p3D-GFP plasmid, respectively. We are also thankful to OIE/National Foot-and-Mouth Disease Reference Laboratory of China for providing the virus isolates, and Division of Quality Management of China Agricultural Veterinary Biological Science and Technology Co., LTD, for the necessary facilities for our experiments. This work was supported by grants from China's Ministry of Agriculture, Genetically Modified Organisms Breeding Technology Major Program (no. 2009ZX08008-010B) (2009ZX08008-010B).

Author details

¹State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, Gansu, P. R. of China. ²Research & Development Department, China Agricultural Veterinary Biological Science and Technology Co., LTD, Lanzhou 730046, Gansu, P. R. of China. ³China Animal Disease Prevention Control Center, Beijing 100125, P. R. of China.

Received: 22 September 2013 Accepted: 27 December 2013
Published: 6 January 2014

References

1. Grubman MJ, Baxt B: **Foot-and-mouth disease.** *Clin Microbiol Rev* 2004, **17**:465–493.

2. Alexandersen S, Mowat N: **Foot-and-mouth disease: host range and pathogenesis.** *Curr Top Microbiol Immunol* 2005, **288**:9–42.
3. Belsham GJ: **Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family: aspects of virus protein synthesis, protein processing and structure.** *Prog Biophys Mol Biol* 1993, **69**:241–260.
4. Bachrach HL: **Foot-and-mouth disease.** *Annu Rev Microbiol* 1968, **22**:201–244.
5. Brown F: **The history of research in foot-and-mouth disease.** *Virus Res* 2003, **91**:3–7.
6. Kitching RP: **Global epidemiology and prospects for control of foot-and-mouth disease.** *Curr Microbiol Immunol* 2005, **288**:133–148.
7. Sobrino F, Saiz M, Jimenez-clavero MA, Nunez JI, Rosas MF, Baranowski E, Ley V: **Foot-and-mouth disease virus: a long known virus, but a current threat.** *Vet Res* 2001, **32**:1–30.
8. Mason PW, Grubman MJ, Baxt B: **Molecular basis of pathogenesis of FMDV.** *Virus Res* 2003, **91**:9–32.
9. Ryan MD, Donnelly MLL, Flint M, Cowton VM, Luke G, Hughes LE, Knox C, De Felipe P: **Foot-and-mouth disease virus proteinases.** In *Foot-and Mouth Disease Current Perspectives*. Edited by Sobrino F, Domingo E. London: Horizon Scientific Press; 2004:53–76.
10. Belsham GJ, Brangwynn JK: **A region of the 5' non-coding region of foot-and-mouth disease virus RNA directs efficient internal initiation of protein synthesis within cells; interaction with the role of the L protease in translational control.** *J Virol* 1990, **64**:5389–5395.
11. Kuhn R, Luz N, Beck E: **Functional analysis of the internal translation initiation site of foot-and-mouth disease virus.** *J Virol* 1990, **64**:4625–4631.
12. Piliipenko EV, Blinov VM, Chernov BK, Dmitrieva TM, Agol VI: **Conservation of the secondary structure elements of the 5'-untranslated region of cardiovirus and aphthovirus RNAs.** *Nucl Acids Res* 1989, **17**:5701–5711.
13. Belsham GJ, Martinez-Salas E: **Genome organization, translation and replication of foot-and-mouth disease virus RNA.** In *Foot-and-Mouth Disease Current Perspectives*. Edited by Sobrino F, Domingo E. London: Horizon Scientific Press; 2004:19–52.
14. Belsham GJ: **Translation and replication of FMDV RNA.** *Curr Top Microbiol Immunol* 2005, **288**:43–70.
15. Domingo E, Ruiz-Jarabo CM, Sierra S, Arias A, Pariente N, Baranowski E, Escarmis C: **Emergence and selection of RNA virus variant: memory and extinction.** *Virus Res* 2001, **82**:39–44.
16. Domingo E, Baranowski E, Escarmis C, Sobrino F, Holland JJ: **Error frequencies of picornavirus RNA polymerases: evolutionary implications for viral populations.** In *Molecular Biology of Picornaviruses*. Edited by Semler BL, Wimmer E. Washington: DC: ASM Press; 2002:285–298.
17. Cottam EM, Haydon DT, Paton DJ, Gloster J, Wilesmith JW, Ferris NP, Hutchings GH, King DP: **Molecular epidemiology of the foot-and-mouth disease virus outbreak in the United Kingdom in 2001.** *J Virol* 2006, **80**:11274–11282.
18. Martinez MA, Carrillo C, Gonzalez-Candelas F, Moya A, Domingo E, Sobrino F: **Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies.** *J Virol* 1991, **65**:3954–3957.
19. Domingo E, Escarmis C, Martinez MA, Martinez-Salas E, Mateu MG: **Foot-and-mouth disease virus populations are quasispecies.** *Curr Top Microbiol Immunol* 1992, **176**:33–47.
20. Ruiz-Jarabo CM, Arias M, Baranowski E, Escarmis C, Domingo E: **Memory in viral quasispecies.** *J Virol* 2000, **74**:3543–3547.
21. Domingo E, Pariente N, Airaksinen A, Gonzalez-Lopez C, Sierra S, Herrera M, Grande-Perez A, Lowenstein PR, Manrubia SC, Lazaro E, Escarmis C: **Foot-and-mouth disease virus evolution: exploring pathways towards virus extinction. populations are quasispecies.** *Curr Top Microbiol Immunol* 2005, **288**:149–173.
22. Domingo E, Escarmis C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, Nunez JI, Sobrino F: **Evolution of foot-and-mouth disease virus.** *Virus Res* 2003, **91**:47–63.
23. Domingo E, Escarmis C, Lazaro E, Manrubia SC: **Quasispecies dynamics and RNA virus extinction.** *Virus Res* 2005, **107**:129–139.
24. Doel TR: **FMD vaccines.** *Virus Res* 2003, **91**:81–99.
25. Yang B, Lan X, Li X, Yin X, Li B, Han X, Li Y, Zhang Z, Liu J: **A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice.** *Vaccine* 2008, **26**:5477–5483.
26. Chen W, Yan W, Du Q, Fei L, Liu M, Ni Z, Sheng Z, Zheng Z: **RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice.** *J Virol* 2004, **78**:6900–6907.
27. Kahana R, Kuznetsova L, Rogel A, Shemesh M, Hai D, Yadin H, Stram Y: **Inhibition of foot-and-mouth disease virus replication by small interfering RNA.** *J Gen Virol* 2004, **85**:3213–3217.
28. Grubman MJ, De los Santos T: **Rapid control of foot-and-mouth disease outbreaks: is RNAi a possible solution?** *Trends Immunol* 2005, **26**:65–68.
29. Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, Fei L, Liu Y, Zuo X, Yang F, Lu Y, Zheng Z: **Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both *in vitro* and *in vivo*.** *J Virol* 2006, **80**:3559–3566.
30. Kim SM, Lee KN, Park JY, Ko YJ, Joo YS, Kim HS, Park JH: **Therapeutic application of RNA interference against foot-and-mouth disease virus *in vitro* and *in vivo*.** *Antiviral Res* 2008, **80**:178–184.
31. Wang PY, Ren Y, Guo ZR, Chen CF: **Inhibition of foot-and-mouth disease virus replication *in vitro* and *in vivo* by small interfering RNA.** *Virus Res* 2008, **136**:5–86.
32. Lv K, Guo YJ, Zhang YL, Wang KY, Li K, Zhu Y, Sun SH: **Transient inhibition of foot-and-mouth disease virus replication by siRNAs silencing VP1 protein coding region.** *Res Vet Sci* 2009, **86**:443–452.
33. Cong W, Cui SQ, Chen JL, Zuo XP, Lu YG, Yan WY, Zheng ZX: **Construction of a multiple targeting RNAi plasmid that inhibits target gene expression and FMDV replication in BHK-21 cells and suckling mice.** *Vet Res Commun* 2010, **34**:335–346.
34. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B: **Human immunodeficiency virus type 1 escape from RNA interference.** *J Virol* 2003, **77**:11531–11535.
35. Pusch O, Boden D, Silbermann R, Lee F, Tucker L, Ramratnam B: **Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA.** *Nucleic Acids Res* 2003, **31**:6444–6449.
36. Gitlin L, Stone JK, Andino R: **Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches.** *J Virol* 2005, **79**:1027–1035.
37. Sabariego R, Giménez-Barcons M, Tàpia N, Clotet B, Martínez MA: **Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.** *J Virol* 2006, **80**:571–577.
38. Kim SM, Lee KN, Lee SJ, Ko YJ, Lee HS, Kweon CH, Kim HS, Park JH: **Multiple shRNAs driven by U6 and CMV promoter enhances efficiency of antiviral effects against foot-and-mouth disease virus.** *Antiviral Res* 2010, **87**:307–317.
39. Nilsen TW: **Mechanisms of microRNA-mediated gene regulation in animal cells.** *Trends Genet* 2007, **23**:243–249.
40. Filipowicz W, Bhattacharyya SN, Sonenberg N: **Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?** *Nat Rev Genet* 2008, **9**:102–114.
41. Du JZ, Gao SD, Luo JH, Zhang GF, Cong GZ, Shao JJ, Lin T, Cai XP, Chang HY: **Effective inhibition of foot-and-mouth disease virus (FMDV) replication *in vitro* by vector-delivered microRNAs targeting the 3D gene.** *Virus Res* 2011, **8**:292.
42. Carrington JC, Ambros V: **Role of microRNAs in plant and animal development.** *Science* 2003, **301**:336–338.
43. Pillai RS, Bhattacharyya SN, Filipowicz W: **Repression of protein synthesis by miRNAs: how many mechanisms?** *Trends Cell Biol* 2007, **17**:118–126.
44. Bartel DP: **MicroRNAs: target recognition and regulatory functions.** *Cell* 2009, **136**:215–233.
45. He L, Hannon GJ: **MicroRNAs: small RNAs with a big role in gene regulation.** *Nat Rev Genet* 2004, **5**:522–531.
46. Sonkoly E, Pivarcsi A: **Advances in microRNAs: implications for immunity and inflammatory diseases.** *J Cell Mol Med* 2009, **13**:24–38.
47. Fernández-Miragall O, Martínez-Salas E: **Structural organization of a viral IRES depends on the integrity of the GNRA motif.** *RNA* 2003, **9**:1333–1344.
48. Drew J, Belsham GJ: **Trans-complementation by RNA of defective FMDV internal ribosome entry site elements.** *J Virol* 1994, **68**:697–703.
49. Ramos R, Martínez-Salas E: **Long-range RNA interactions between structural domains of the aphthovirus internal ribosome entry site (IRES).** *RNA* 1999, **5**:1374–1383.
50. Roberts LO, Belsham GJ: **Complementation of defective picornavirus internal ribosome entry site (IRES) elements by the coexpression of fragments of the IRES.** *Virology* 1997, **227**:53–62.
51. Gutiérrez A, Martínez-Salas E, Pintado B, Sobrino F: **Specific inhibition of aphthovirus infection by RNAs transcribed from both the 5' and the 3' noncoding regions.** *J Virol* 1994, **68**:7426–7432.
52. Biegerigo P, Rosas MF, Zamora E, Martínez-Salas E, Sobrino F: **Heterotypic inhibition of foot-and-mouth disease virus infection by combinations of**

- RNA transcripts corresponding to the 5' and 3' regions. *Antiviral Res* 1999, **44**:133–141.
53. Rosas MF, Martínez-Salas E, Sobrino F: Stable expression of antisense RNAs targeted to the 5' non-coding region confers heterotypic inhibition to foot-and-mouth disease virus infection. *J Gen Virol* 2003, **84**:393–402.
 54. Rodríguez-Pulido M, Sobrino F, Borrego B, Sáiz M: Inoculation of newborn mice with non-coding regions of foot-and-mouth disease virus RNA can induce a rapid, solid and wide-range protection against viral infection. *Antiviral Res* 2011, **92**:500–504.
 55. Joyappa DH, Sasi S, Ashok KC, Reddy GR, Suryanarayana W: The plasmid constructs producing shRNA corresponding to the conserved 3D polymerase of foot and mouth disease virus protects guinea pigs against challenge virus. *Vet Res Commun* 2009, **33**:263–271.
 56. De Los Santos T, Wu Q, De Avila Botton S, Grubman MJ: Short hairpin RNA targeted to the highly conserved 2B nonstructural protein coding region inhibits replication of multiple serotypes of foot-and-mouth disease virus. *Virology* 2005, **335**:222–231.
 57. Stassinopoulos IA, Belsham GJ: A novel protein-RNA binding assay: functional interactions of the foot-and-mouth disease virus internal ribosome entry site with cellular proteins. *RNA* 2001, **7**:114–122.
 58. Martínez-Salas E: The impact of RNA structure on picornavirus IRES activity. *Trends Microbiol* 2008, **16**:230–237.
 59. Wilson JA, Richardson CD: Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. *J Virol* 2005, **79**:7050–7058.
 60. Bai X, Li P, Bao H, Liu Z, Li D, Lu Z, Cao Y, Shang Y, Shao J, Chang H, Luo J, Liu X: Evolution and molecular epidemiology of foot-and-mouth disease virus in China. *Chin Sci Bull* 2011, **56**:2191–2201.
 61. Cong W, Jin H, Jiang C, Yan W, Liu M, Chen J, Zuo X, Zheng Z: Attenuated *Salmonella choleraesuis*-mediated RNAi targeted to conserved regions against foot-and-mouth disease virus in guinea pigs and swine. *Vet Res* 2010, **41**:30.
 62. Bao HF, Li D, Sun P, Zhou Q, Hu J, Bai XW, Fu YF, Lu ZJ, Liu ZX: The infectivity and pathogenicity of a foot-and-mouth disease virus persistent infection strain from oesophageal-pharyngeal fluid of a Chinese cattle in 2010. *Virol J* 2011, **8**:536.
 63. Escarmis C, Carrillo EC, Ferrer M, Arriaza JF, Lopez N, Tami C, Verdaguer N, Domingo E, Franze-Fernández MT: Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism. *J Virol* 1998, **72**:10171–10179.
 64. Vagnozzi A, Stein DA, Iversen PL, Rieder E: Inhibition of foot-and-mouth disease virus infections in cell cultures with antisense morpholino oligomers. *J Virol* 2007, **81**:11669–11680.
 65. Fajardo T Jr, Rosas MF, Sobrino F, Martínez-Salas E: Exploring IRES region accessibility by interference of foot-and-mouth disease virus infectivity. *PLoS One* 2012, **7**:e41382.
 66. Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Anan C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Solà M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R: Picornavirus non-structural proteins as targets for new anti-virals with broad activity. *Antiviral Res* 2011, **89**:204–218.
 67. Cao YM, Lu ZJ, Sun P, Fu YF, Tian FP, Hao XF, Bao HF, Liu XT, Liu ZX: A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-cell immunogen shows enhanced immunogenicity in mice. *Virol J* 2011, **8**:77.
 68. Liu XS, Wang YL, Zhang YG, Fang YZ, Pan L, Lu JL, Zhou P, Zhang ZW, Jiang ST: Identification of H-2d restricted T cell epitope of foot-and-mouth disease virus structural protein VP1. *Virol J* 2011, **8**:426.

doi:10.1186/1743-422X-11-1

Cite this article as: Chang et al.: Multiple microRNAs targeted to internal ribosome entry site against foot-and-mouth disease virus infection *in vitro* and *in vivo*. *Virology Journal* 2013 **11**:1.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

